Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Cytosorbents Crp is a medical devices business based in the US. Cytosorbents Crp shares (CTSO) are listed on the NASDAQ and all prices are listed in US Dollars. Cytosorbents Crp employs 221 staff and has a trailing 12-month revenue of around $36.1 million.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $2.37 |
|---|---|
| 52-week range | $1.03 - $4.15 |
| 50-day moving average | $1.54 |
| 200-day moving average | $1.90 |
| Wall St. target price | $9.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.68 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.37 from 2023-01-27
| 1 week (2023-01-23) | 10.75% |
|---|---|
| 1 month (2022-12-30) | 52.90% |
| 3 months (2022-10-28) | 36.21% |
| 6 months (2022-07-29) | 3.95% |
| 1 year (2022-01-28) | -32.09% |
|---|---|
| 2 years (2021-01-29) | -77.41% |
| 3 years (2020-01-30) | 4.96 |
| 5 years (2018-01-30) | 7.6 |
| Revenue TTM | $36.1 million |
|---|---|
| Gross profit TTM | $32.5 million |
| Return on assets TTM | -26.97% |
| Return on equity TTM | -75.36% |
| Profit margin | -114.61% |
| Book value | $0.90 |
| Market capitalisation | $101.7 million |
TTM: trailing 12 months
We're not expecting Cytosorbents Crp to pay a dividend over the next 12 months.
Cytosorbents Crp's shares were split on a 1:25 basis on 4 December 2014. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytosorbents Crp shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Cytosorbents Crp shares which in turn could have impacted Cytosorbents Crp's share price.
Over the last 12 months, Cytosorbents Crp's shares have ranged in value from as little as $1.03 up to $4.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytosorbents Crp's is 0.5051. This would suggest that Cytosorbents Crp's shares are less volatile than average (for this exchange).
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.